Posted by Michael Wonder on 01 Jul 2025
Unicycive Therapeutics announces receipt of complete response letter for oxylanthanum carbonate for the treatment of hyperphosphataemia in patients with chronic kidney disease on dialysis
30 June 2025 - No other concerns stated, including pre-clinical, clinical, or safety data.
Unicycive Therapeutics today announced that the US FDA has issued a complete response letter for its new drug application for oxylanthanum carbonate to treat hyperphosphataemia in patients with chronic kidney disease on dialysis.
